Want to see NKTX full AI Analyst Report?
NKTX Stock Chart & Stats
$2.63
-$0.01(-0.44%)
At close: 4:00 PM EDT
$2.63
-$0.01(-0.44%)
Day’s Range― - ―
52-Week Range$1.70 - $3.72
Previous Close$2.28
Volume807.02K
Average Volume (3M)575.88K
Market Cap
$201.27M
Enterprise Value$101.60
Total Cash (Recent Filing)$182.76M
Total Debt (Recent Filing)$73.54M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Nov 11, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.57
Shares Outstanding71,624,794
10 Day Avg. Volume593,294
30 Day Avg. Volume575,883
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.44
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.75Price Target Upside346.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.59
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Moderate LeverageModerate leverage limits the balance-sheet burden relative to equity and is less restrictive than a highly debt-funded profile. This gives Nkarta some financial flexibility while it develops its pipeline, although continued losses remain the more important capital-allocation constraint.
Free Cash Flow TrendThe improvement in free cash flow relative to some prior periods suggests that cash deterioration is not accelerating across every reporting measure. If sustained, this could extend operating flexibility, though the company remains materially cash-flow negative and still depends on financing.
Regular Shareholder OversightAnnual say-on-pay voting creates a recurring mechanism for shareholders to review executive compensation and reinforces governance accountability. While it does not directly improve clinical or financial execution, consistent oversight can support disciplined management incentives over the medium term.
Bears Say
Pre-revenue Business ModelNkarta has no established commercial revenue base, so its ability to fund research and operations internally remains unproven. Until a product generates sales, the company’s financial outlook depends heavily on clinical progress and continued access to external capital.
Persistent Operating LossesLarge recurring operating and net losses show that the current business is not close to self-funding. Continued losses can consume equity and increase the amount of capital required before commercialization, leaving results highly dependent on successful development and eventual product launch.
Material Cash Burn And Declining EquitySustained negative free cash flow requires ongoing financing to support operations, while falling equity indicates that losses are eroding the company’s capital base. This combination can reduce strategic flexibility and increase dilution or funding pressure before revenues emerge.
Nkarta News
NKTX FAQ
What was Nkarta’s price range in the past 12 months?
Nkarta lowest stock price was $1.70 and its highest was $3.72 in the past 12 months.
What is Nkarta’s market cap?
Nkarta’s market cap is $201.27M.
When is Nkarta’s upcoming earnings report date?
Nkarta’s upcoming earnings report date is Nov 11, 2026 which is in 60 days.
How were Nkarta’s earnings last quarter?
Nkarta released its earnings results on Aug 10, 2026. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.36 by -$0.18.
Is Nkarta overvalued?
According to Wall Street analysts Nkarta’s price is currently Undervalued.
Does Nkarta pay dividends?
Nkarta does not currently pay dividends.
What is Nkarta’s EPS estimate?
Nkarta’s EPS estimate is -0.4.
How many shares outstanding does Nkarta have?
Nkarta has 71,624,794 shares outstanding.
What happened to Nkarta’s price movement after its last earnings report?
Nkarta reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.36. Following the earnings report the stock price went down -5.285%.
Which hedge fund is a major shareholder of Nkarta?
Currently, no hedge funds are holding shares in NKTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nkarta Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.75 (346.77% Upside)
$11.75 (346.77% Upside)
Blogger Sentiment
Bullish
NKTX Sentiment 100%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Increased
By 587.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.57%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-24.69%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Nkarta
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
NKTX Stock 12 Month Forecast
Average Price Target
$11.75
▲(346.77% Upside)
Technical Analysis
Ownership Overview
20.62% Insiders
7.76% Mutual Funds
46.00% Other Institutional Investors
18.50% Public Companies and
Individual Investors